Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Historical Holders from Q4 2021 to Q3 2025

Symbol
XLO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
53,514,204
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
22,051,916
Holdings value
$18,613,906
% of all portfolios
0%
Number of holders
36
Number of buys
10
Number of sells
-7
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 19.9% 0% $7,748,179 +$1,101,200 10,613,944 +16.6% GILEAD SCIENCES, INC. 30 Jun 2025
Frazier Life Sciences Public Fund, L.P. 9.9% 0% $5,942,942 +$1,747,492 8,141,017 +41.7% Frazier Life Sciences Public Fund, L.P. 30 Jun 2025
Point72 Asset Management, L.P. 9.9% +38.6% $6,743,200 +$3,371,600 8,000,000 +100% Point72 Asset Management, L.P. 30 Sep 2025
Coastlands Capital LP 9.99% $3,742,248 5,346,069 Coastlands Capital LP 04 Dec 2025
AbbVie Inc. 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025
STEMPOINT CAPITAL LP 7.2% $3,371,600 4,000,000 StemPoint Capital LP 30 Sep 2025

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 22,051,916 $18,613,906 -$1,227,318 $0.8427 36
2025 Q2 23,795,263 $16,179,092 +$854,217 $0.6799 35
2025 Q1 22,528,206 $16,318,555 -$3,181,066 $0.7244 35
2024 Q4 25,814,355 $24,660,128 -$144,644 $0.955 34
2024 Q3 15,911,945 $12,534,583 +$1,128,156 $0.7877 32
2024 Q2 14,508,823 $13,746,216 +$1,785,264 $0.9475 31
2024 Q1 12,460,895 $13,460,257 -$2,676,053 $1.08 30
2023 Q4 16,426,281 $9,034,716 -$1,543,598 $0.55 33
2023 Q3 15,860,160 $33,465,952 -$314,935 $2.11 30
2023 Q2 16,002,286 $41,925,598 -$192,245 $2.62 32
2023 Q1 16,072,057 $50,979,505 +$461,644 $3.17 32
2022 Q4 15,926,513 $42,841,966 -$709,927 $2.69 28
2022 Q3 16,606,568 $48,328,000 -$3,750,524 $2.91 28
2022 Q2 17,880,380 $52,211,910 -$3,647,986 $2.92 29
2022 Q1 18,775,939 $132,746,000 -$2,569,332 $7.07 41
2021 Q4 18,324,586 $269,421,063 +$225,248,000 $16 41